Oxford Biomedica plc (LON:OXB – Get Free Report) passed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of GBX 515.39 and traded as low as GBX 502.05. Oxford Biomedica shares last traded at GBX 513, with a volume of 263,782 shares traded.
Analyst Ratings Changes
A number of equities research analysts have commented on OXB shares. Jefferies Financial Group reissued a “buy” rating and set a GBX 827 price objective on shares of Oxford Biomedica in a report on Monday, October 26th. Deutsche Bank reaffirmed a “hold” rating and issued a GBX 595 target price on shares of Oxford Biomedica in a research note on Wednesday, September 2nd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a GBX 900 target price on shares of Oxford Biomedica in a research report on Tuesday, September 1st. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of GBX 818.
View Our Latest Research Report on OXB
Oxford Biomedica Price Performance
The company has a 50 day moving average price of GBX 515.39 and a 200 day moving average price of GBX 585.66. The company has a market capitalization of £606.64 million, a price-to-earnings ratio of -15.63 and a beta of 1.11. The company has a current ratio of 2.21, a quick ratio of 1.67 and a debt-to-equity ratio of 273.08.
Oxford Biomedica (LON:OXB – Get Free Report) last released its earnings results on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) earnings per share for the quarter. Oxford Biomedica had a negative return on equity of 54.51% and a negative net margin of 23.23%. As a group, equities research analysts forecast that Oxford Biomedica plc will post -31.08 earnings per share for the current year.
Insider Buying and Selling
In other news, insider Roch Doliveux acquired 20,250 shares of the stock in a transaction that occurred on Wednesday, September 23rd. The stock was purchased at an average cost of GBX 505 per share, for a total transaction of £102,262.50. 43.30% of the stock is currently owned by insiders.
Oxford Biomedica Company Profile
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.
Featured Stories
- Five stocks we like better than Oxford Biomedica
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.
